Global Pharmaceutical Glass Packaging Market Research Report Forecast to 2030

List of Tables

Pharmaceutical Glass Packaging Market Forecast till 2030

Market Overview

The growth of the Pharmaceutical Glass Packaging Market is increasing at a faster rate. The pharmaceutical industry is booming due to the availability of crucial clinical drugs and other services, and the use of packaging is vital to protect these medicines. Glass packaging, in particular, is gaining popularity due to its advantages, such as protecting the product from contamination and damage, increasing its shelf life, and preventing carbon dioxide from entering the package.

The demand for pharmaceutical drugs and medicines is expected to be high in the coming years, leading to an increase in sales of pharmaceutical glass packaging. The segment of injectable medicines is experiencing the greatest demand, and the use of glass packaging helps to prevent the medicines from breaking down due to external factors..

Segment Overview

The growth of the Pharmaceutical Glass Packaging Market is fuelled by the growing demand for packaging in the pharmaceutical industry. Longer shelf life and advancements in packaging technology are factors contributing to market growth. The growth rate for vials is expected to be second highest after ampoules, driven by their high analytical performance and sustainability. Ampoules are expected to grow at a faster pace, and type III glass is projected to show significant growth. The generic drugs segment is expected to grow at the fastest rate.

Pharmaceutical glass bottles are categorized into two types based on size, small and large. Large bottles are used for packaging reagents, transfusion and infusion bottles, while small bottles are for syrup and oral liquid packaging. The small bottle segment is anticipated to grow due to new opportunities such as the increasing consumption of oral tablets packaged in small bottles.

Regional Analysis

North America plays a crucial role in the pharmaceutical glass packaging market, with strong investment in R&D and product innovation in the glass packaging sector. The demand for pharmaceutical glass packaging is fueled by stringent regulations and policies in the US and Canada, growing drug consumption, and the rapid growth of the pharmaceutical industry.

The US is the leading player in the North American pharmaceutical glass packaging market, as the rapidly expanding drug market drives a continuous increase in demand for glass packaging in the pharmaceutical sector. The growth of the pharmaceutical glass packaging market in the US is further supported by the rising healthcare spending in the country.

Major Players

The key players in the market are Shandong Qidu Pharmaceutical Co.,Ltd. (China), West Pharmaceutical Services, Inc. (U.S.), SCHOTT Pharmaceutical Packaging (U.S.), Ardagh Group S.A. (Luxembourg), Piramal Glass (India), Bormioli Rocco SpA (Italy), Nipro Corporation (Japan), SGD Pharma (France), and Stolzle-Oberglas Gmbh (Austria) and Gerresheimer AG (Germany).

COVID 19 Impacts

The COVID-19 pandemic has left a lasting impact on the pharmaceutical industry, causing steady growth and high demand for medical supplies and treatments. The sudden increase in demand for pharmaceutical drugs due to the pandemic has positively affected the market, and it is expected to reach new heights once COVID-19 vaccines are approved and distributed globally.

For example, the United States is producing millions of surplus vaccine doses packaged in large multi-dose vials, which are either used domestically or exported to other countries. has posed challenges for manufacturers, despite the demand from state officials.

Currently, most vaccines in the U.S. are distributed in the form of single-dose vials or prefilled syringes. However, the COVID-19 vaccines were initially distributed through multi-dose vials due to the urgency and quick production needed during the early months of the inoculation campaign in the country.

Product Code: MRFR/PNT/3741-CR

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

1.1 EXECUTIVE SUMMARY
- 1.1.1 GLOBAL PHARMACEUTICAL GLASS PACKAGING MARKET, BY PRODUCT
- 1.1.2 GLOBAL PHARMACEUTICAL GLASS PACKAGING MARKET, BY MATERIAL TYPE
- 1.1.3 GLOBAL PHARMACEUTICAL GLASS PACKAGING MARKET, BY APPLICATION
- 1.1.4 GLOBAL PHARMACEUTICAL GLASS PACKAGING MARKET, BY REGION

2 MARKET INTRODUCTION

2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

3.1 RESEARCH PROCESS
3.2 PRIMARY RESEARCH
3.3 SECONDARY RESEARCH
3.4 MARKET SIZE ESTIMATION
3.5 FORECAST MODEL
3.6 LIST OF ASSUMPTIONS

4 MARKET DYNAMICS

4.1 INTRODUCTION
4.2 DRIVERS
- 4.2.1 EXTENDING THE SHELF LIFE OF PRODUCTS
- 4.2.2 TECHNOLOGICAL DEVELOPMENTS IN PHARMACEUTICAL GLASS PACKAGING
- 4.2.3 INCREASING DEMAND FROM THE PHARMACEUTICAL INDUSTRY
- 4.2.4 DRIVERS IMPACT ANALYSIS
4.3 RESTRAINT
- 4.3.1 GROWING DEMAND FOR PLASTIC PACKAGING
- 4.3.2 RESTRAINT IMPACT ANALYSIS
4.4 OPPORTUNITY
- 4.4.1 INCREASING DEMAND IN EMERGING ECONOMIES
4.5 REGULATORY FRAMEWORK
- 4.5.1 ASPECTS OF PACKAGING
  - 4.5.1.1 GENERAL CONSIDERATIONS
  - 4.5.1.2 COMPLIANCE
- 4.5.2 PACKAGING MATERIALS AND CLOSURES
- 4.5.3 QUALITY ASSURANCE ASPECTS OF PACKAGING
  - 4.5.3.1 GENERAL CONSIDERATIONS
  - 4.5.3.2 QUALITY CONTROL
  - 4.5.3.2.1 SAMPLING
  - 4.5.3.2.2 TESTING PROGRAMME
  - 4.5.3.3 INSPECTION AND AUDIT
  - 4.5.3.3.1 RULES
  - 4.5.3.3.2 AUDITS OF SUPPLIERS
- 4.5.4 PROTECTION OF THE ENVIRONMENT
  - 4.5.4.1 PACKAGING WASTE
  - 4.5.4.2 WASTE POLICIES
4.6 PROFIT MARGIN ANALYSIS
4.7 RELATION BETWEEN CAPACITY UTILIZATION RATE & PRODUCT PRICES
- 4.7.1 LOW UTILIZATION
- 4.7.2 FULL UTILIZATION
- 4.7.3 OVER-UTILIZATION
4.8 CAPAPCITY UTILISATION ANALYSIS
- 4.8.1 AVERAGE CAPACITY UTILISATION RANGE OF PROMINENT PLAYERS, 2022-2030
- 4.8.2 ESTIMATED PLANNED AND FORECASTED CAPACITY EXPANSION BY PROMINENT PLAYERS
4.9 COVID-19 IMPACT ANALYSIS
- 4.9.1 ECONOMIC IMPACT
  - 4.9.1.1 IMPACT ON THE OVERALL PACKAGING INDUSTRY
- 4.9.2 IMPACT ON PRODUCTION
- 4.9.3 IMPACT ON GLASS PACKAGING MARKET
  - 4.9.3.1 IMPACT ON SUPPLY CHAIN
  - 4.9.3.2 IMPACT ON RAW MATERIAL
  - 4.9.3.3 CASH FLOW CONSTRAINTS
- 4.9.4 IMPACT ON WORLD TRADE

5 MARKET FACTOR ANALYSIS

5.1 SUPPLY CHAIN ANALYSIS
- 5.1.1 RAW MATERIAL SUPPLY
- 5.1.2 MANUFACTURING
- 5.1.3 DISTRIBUTION CHANNELS
- 5.1.4 END USERS
5.2 PORTER'S FIVE FORCES MODEL
- 5.2.1 THREAT OF NEW ENTRANTS
- 5.2.2 BARGAINING POWER OF SUPPLIERS
- 5.2.3 THREAT OF SUBSTITUTES
- 5.2.4 BARGAINING POWER OF BUYERS
- 5.2.5 INTENSITY OF RIVALRY

6 GLOBAL PHARMACEUTICAL GLASS PACKAGING MARKET, BY PRODUCT

6.1 OVERVIEW
- 6.1.1 VIALS
- 6.1.2 BOTTLES & JARS
- 6.1.3 CARTRIDGES & SYRINGES
- 6.1.4 AMPOULES

7 GLOBAL PHARMACEUTICAL GLASS PACKAGING MARKET, BY MATERIAL TYPE

7.1 OVERVIEW
- 7.1.1 TYPE I
- 7.1.2 TYPE II
- 7.1.3 TYPE III

8 GLOBAL PHARMACEUTICAL GLASS PACKAGING MARKET, BY APPLICATION

8.1 OVERVIEW
- 8.1.1 GENERIC DRUGS
- 8.1.2 BRANDED DRUGS
- 8.1.3 BIOLOGICAL DRUGS

9 GLOBAL PHARMACEUTICAL GLASS PACKAGING MARKET, BY REGION

9.1 OVERVIEW
9.2 NORTH AMERICA
- 9.2.1 US
- 9.2.2 CANADA
- 9.2.3 MEXICO
9.3 EUROPE
- 9.3.1 GERMANY
- 9.3.2 UK
- 9.3.3 FRANCE
- 9.3.4 ITALY
- 9.3.5 REST OF EUROPE
9.4 ASIA-PACIFIC
- 9.4.1 CHINA
- 9.4.2 JAPAN
- 9.4.3 INDIA
- 9.4.4 REST OF ASIA-PACIFIC
9.5 LATIN AMERICA
- 9.5.1 BRAZIL
- 9.5.2 ARGENTINA
- 9.5.3 REST OF LATIN AMERICA
9.6 MIDDLE EAST & AFRICA
- 9.6.1 UAE
- 9.6.2 SAUDI ARABIA
- 9.6.3 SOUTH AFRICA
- 9.6.4 REST OF MIDDLE EAST & AFRICA

10 COMPETITIVE LANDSCAPE

10.1 INTRODUCTION
10.2 COMPETITIVE OVERVIEW
10.3 MARKET SHARE ANALYSIS
10.4 COMPETITIVE BENCHMARKING
10.5 GERRESHEIMER AG: LEADING PLAYER IN TERMS OF NUMBER OF DEVELOPMENTS IN GLOBAL PHARMACEUTICAL GLASS PACKAGING MARKET
10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
- 10.6.1 PRODUCT LAUNCHES/SERVICE DEPLOYMENTS
- 10.6.2 EXPANSIONS
- 10.6.3 MERGERS & ACQUISITIONS/INVESTMENTS
- 10.6.4 PARTNERSHIPS/CONTRACTS & AGREEMENTS

11 COMPANY PROFILES

11.1 GERRESHEIMER AG
- 11.1.1 COMPANY OVERVIEW
- 11.1.2 FINANCIAL OVERVIEW
- 11.1.3 PRODUCTS OFFERED
- 11.1.4 KEY DEVELOPMENTS
- 11.1.5 SWOT ANALYSIS
- 11.1.6 KEY STRATEGIES
11.2 NIPRO CORPORATION
- 11.2.1 COMPANY OVERVIEW
- 11.2.2 FINANCIAL OVERVIEW
- 11.2.3 PRODUCTS OFFERED
- 11.2.4 KEY DEVELOPMENTS
- 11.2.5 SWOT ANALYSIS
- 11.2.6 KEY STRATEGIES
11.3 SCHOTT AG
- 11.3.1 COMPANY OVERVIEW
- 11.3.2 FINANCIAL OVERVIEW
- 11.3.3 PRODUCTS OFFERED
- 11.3.4 KEY DEVELOPMENTS
- 11.3.5 SWOT ANALYSIS
- 11.3.6 KEY STRATEGIES
11.4 SGD PHARMA
- 11.4.1 COMPANY OVERVIEW
- 11.4.2 FINANCIAL OVERVIEW
- 11.4.3 PRODUCTS OFFERED
- 11.4.4 KEY DEVELOPMENTS
11.5 SHANDONG QIDU PHARMACEUTICAL CO., LTD.
- 11.5.1 COMPANY OVERVIEW
- 11.5.2 FINANCIAL OVERVIEW
- 11.5.3 PRODUCTS OFFERED
- 11.5.4 KEY DEVELOPMENTS
11.6 BORMIOLI PHARMA S.P.A.
- 11.6.1 COMPANY OVERVIEW
- 11.6.2 FINANCIAL OVERVIEW
- 11.6.3 PRODUCTS OFFERED
- 11.6.4 KEY DEVELOPMENTS
11.7 ARDAGH GROUP S.A.
- 11.7.1 COMPANY OVERVIEW
- 11.7.2 FINANCIAL OVERVIEW
- 11.7.3 PRODUCTS OFFERED
- 11.7.4 KEY DEVELOPMENTS
- 11.7.5 SWOT ANALYSIS
- 11.7.6 KEY STRATEGIES
11.8 WEST PHARMACEUTICAL SERVICES, INC.
- 11.8.1 COMPANY OVERVIEW
- 11.8.2 FINANCIAL OVERVIEW
- 11.8.3 PRODUCTS OFFERED
- 11.8.4 KEY DEVELOPMENTS
- 11.8.5 SWOT ANALYSIS
- 11.8.6 KEY STRATEGIES
11.9 PIRAMAL ENTERPRISES LIMITED
- 11.9.1 COMPANY OVERVIEW
- 11.9.2 FINANCIAL OVERVIEW
- 11.9.3 PRODUCTS OFFERED
- 11.9.4 KEY DEVELOPMENTS
- 11.9.5 SWOT ANALYSIS
- 11.9.6 KEY STRATEGIES
11.10 STOELZLE OBERGLAS GMBH
- 11.10.1 COMPANY OVERVIEW
- 11.10.2 FINANCIAL OVERVIEW
- 11.10.3 PRODUCTS OFFERED
- 11.10.4 KEY DEVELOPMENTS
11.11 ARAB PHARMACEUTICAL GLASS CO.
- 11.11.1 COMPANY OVERVIEW
- 11.11.2 FINANCIAL OVERVIEW
- 11.11.3 PRODUCTS OFFERED
- 11.11.4 KEY DEVELOPMENTS
11.12 SISECAM GROUP
- 11.12.1 COMPANY OVERVIEW
- 11.12.2 FINANCIAL OVERVIEW
- 11.12.3 PRODUCTS OFFERED
- 11.12.4 KEY DEVELOPMENTS
- 11.12.5 SWOT ANALYSIS
- 11.12.6 KEY STRATEGIES
11.13 OWENS-ILLINOIS INC.
- 11.13.1 COMPANY OVERVIEW
- 11.13.2 FINANCIAL OVERVIEW
- 11.13.3 PRODUCTS OFFERED
- 11.13.4 KEY DEVELOPMENTS
- 11.13.5 SWOT ANALYSIS
- 11.13.6 KEY STRATEGIES
11.14 BECTON, DICKINSON AND COMPANY
- 11.14.1 COMPANY OVERVIEW
- 11.14.2 FINANCIAL OVERVIEW
- 11.14.3 PRODUCTS OFFERED
- 11.14.4 KEY DEVELOPMENTS
- 11.14.5 SWOT ANALYSIS
- 11.14.6 KEY STRATEGIES

12 APPENDIX

12.1 REFERENCE